Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende Patientenratgeber
Erweiterte Suche
Anmelden
nach oben
Pituitary
Erschienen in:

26.03.2020 | Prolactinoma

Hyperprolactinemia and bone

verfasst von: Luigi di Filippo, Mauro Doga, Eugenia Resmini, Andrea Giustina

Erschienen in: Pituitary | Ausgabe 3/2020

Einloggen, um Zugang zu erhalten

Abstract

Prolactin (PRL) has direct and indirect effects on bone metabolism. Experimental studies showed that in the presence of high PRL levels bone resorption was increased as well as bone formation was suppressed. Increased PRL levels in humans caused a reduction in sex hormone levels which turn may have detrimental effects on bone. Patients with hyperprolactinemia did have often decreased bone mineral density as well as an increased risk of fractures. Since PRL control may be relevant to bone health it is a clinical open issue the inclusion of skeletal health in future guidelines as indication to proactive screening, prevention and treatment particularly in high risk patients such as hyperprolactinemic women after menopause and patients with drug induced hyperprolactinemia.
Literatur
1.
Bernard V, Jacques YJ, Chanson P, Binart N (2015) New insights in prolactin: pathological implications. Nat Rev Endocrinol 11:265–275PubMed
2.
Melmed S, Casanueva FF, Hoffman AR, Kleinberg DL, Montori V, Schlechte JA, Wass J (2011) Diagnosis and treatment of hyperprolactinemia: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 96:273–288PubMed
3.
De Marinis L, Mancini A, Valle D, Bianchi A, Gentilella R, Milardi D, Mascadri C, Giustina A (2000) Effects of galanin on growth hormone and prolactin secretion in anorexia nervosa. Metabolism 49(2):155–159PubMed
4.
Bernard V, Young J, Binart N (2019) Prolactin - a pleiotropic factor in health and disease. Nat Rev Endocrinol 15(6):356–365PubMed
5.
Bole-Feysot C, Goffin V, Edery M, Binart N, Kelly PA (1998) Prolactin (PRL) and its receptor: actions, signal transduction pathways and phenotypes observed in PRL receptor knockout mice. Endocr Rev 19:225–268PubMed
6.
Goffin V, Binart N, Touraine P, Kelly PA (2002) Prolactin: the new biology of an old hormone. Annu Rev Physiol 64:47–67PubMed
7.
Ben-Jonathan N, LaPensee CR, LaPensee EW (2008) What can we learn from rodents about prolactin in humans? Endocr Rev 29:1–41PubMed
8.
Vilar L, Freitas MC, Naves LA, Casulari LA, Azevedo M, Montenegro R, Barros AI, Jr, Faria M, Nascimento GC, Lima JG, Nóbrega LH, Cruz TP, Mota A, Ramos A, Violante A, Lamounier FA, Gadelha MR, Czepielewski MA, Glezer A, Bronstein MD (2008) Diagnosis and management of hyperprolactinemia: results of a Brazilian multicenter study with 1234 patients. J Endocrinol Invest 31:436–444PubMed
9.
Casanueva FF, Molitch ME, Schlechte JA, Abs R, Bonert V, Bronstein MD, Brue T, Cappabianca P, Colao A, Fahlbusch R, Fideleff H, Hadani M, Kelly P, Kleinberg D, Laws E, Marek J, Scanlon M, Sobrinho LG, Wass JA, Giustina A (2006) Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas. Clin Endocrinol 65:265–273
10.
Giustina A, Gola M, Doga M, Rosei EA (2001) Clinical review 136: Primary lymphoma of the pituitary: an emerging clinical entity. J Clin Endocrinol Metab 86(10):4567–4575PubMed
11.
De Marinis L, Bonadonna S, Bianchi A, Maira G, Giustina A (2005) Primary empty sella. J Clin Endocrinol Metab 90(9):5471–5477PubMed
12.
Giustina A, Aimaretti G, Bondanelli M, Buzi F, Cannavò S, Cirillo S, Colao A, De Marinis L, Ferone D, Gasperi M, Grottoli S, Porcelli T, Ghigo E (2010) degli Uberti E: Primary empty sella: why and when to investigate hypothalamic-pituitary function. J Endocrinol Invest. 33(5):343–346PubMed
13.
Carpinteri R, Patelli I, Casanueva FF, Giustina A (2009) Pituitary tumours: inflammatory and granulomatous expansive lesions of the pituitary. Best Pract Res Clin Endocrinol Metab 23(5):639–650PubMed
14.
Giustina A, Mazziotti G, Canalis E (2008) Growth hormone, insulin- like growth factors, and the skeleton. Endocr Rev 29:535–559PubMedPubMedCentral
15.
Arnaldi G, Angeli A, Atkinson AB, Bertagna X, Cavagnini F, Chrousos GP, Fava GA, Findling JW, Gaillard RC, Grossman AB, Kola B, Lacroix A, Mancini T, Mantero F, Newell-Price J, Nieman LK, Sonino N, Vance ML, Giustina A, Boscaro M (2003) Diagnosis and complications of Cushing’s syndrome: a consensus statement. J Clin Endocrinol Metab 88(12):5593–5602PubMed
16.
Frara S, Losa M, Doga M, Formenti AM, Mortini P, Mazziotti G, Giustina A (2018) High prevalence of radiological vertebral fractures in patients with TSH-secreting pituitary adenoma. J Endocr Soc 2(9):1089–1099PubMedPubMedCentral
17.
Bataille-Simoneau N, Gerland K, Chappard D, Basle MF, Mercier L (1996) Expression of prolactin receptors in human osteosarcoma cells. Biochem Biophys Res Commun 229(1):323–328PubMed
18.
Wongdee K, Tulalamba W, Thongbunchoo J, Krishnamra N, Charoenphandhu N (2011) Prolactin alters the mRNA expression of osteoblastderived osteoclastogenic factors in osteoblastlike UMR106 cells. Mol Cell Biochem 349(1–2):195–204PubMed
19.
Seriwatanachai D, Thongchote K, Charoenphandhu N, Pandaranandaka J, Tudpor K, Teerapornpuntakit J, Suthiphongchai T, Krishnamra N (2008) Prolactin directly enhances bone turnover by raising osteoblast expressed receptor activator of nuclear factor kB ligand/osteoprotegerin ratio. Bone 42(3):535–546PubMed
20.
Coss D, Yang L, Kuo CB, Xu X, Luben RA, Walker AM (2000) Effects of prolactin on osteoblast alkaline phosphatase and bone formation in the developing rat. Am J Physiol Endocrinol Metab 279(6):E1216–E1225PubMed
21.
Seriwatanachai D, Krishnamra N, van Leeuwen JP (2009) Evidence for direct effects of prolactin on human osteoblasts: inhibition of cell growth and mineralization. J Cell Biochem 107(4):677–685PubMed
22.
Wang C, Chan V (1982) Divergent effects of prolactin on estrogen and progesterone production by granulosa cells of rat Graafian follicles. Endocrinology 110(4):1085–1093PubMed
23.
Wang C, Hsueh AJ, Erickson GF (1980) Prolactin inhibition of estrogen production by cultured rat granulosa cells. Mol Cell Endocrinol 20(2):135–144PubMed
24.
Krishnamra N, Seemoung J (1996) Effects of acute and long-term administration of prolactin on bone 45Ca uptake, calcium deposit, and calcium resorption in weaned, young, and mature rats. Can J Physiol Pharmacol 74(10):1157–1165PubMed
25.
Thongchote K, Charoenphandhu N, Krishnamra N (2008) High physiological prolactin induced by pituitary transplantation decreases BMD and BMC in the femoral metaphysis, but not in the diaphysis of adult female rats. J Physiol Sci 58(1):39–45PubMed
26.
Adler RA, Farrell ME, Krieg RJ, Deiss WP (1989) Hypogonadism does not mediate urinary calcium loss in pituitary-grafted rats. Metabolism 38(8):805–809PubMed
27.
Piyabhan P, Krishnamra N, Limlomwongse L (2000) Changes in the regulation of calcium metabolism and bone calcium content during growth in the absence of endogenous prolactin and during hyperprolactinemia: a longitudinal study in male and female Wistar rats. Can J Physiol Pharmacol 78(10):757–765PubMed
28.
Mazziotti G, Chiavistelli S, Giustina A (2015) Pituitary diseases and bone. Endocrinol Metab Clin N Am 44(1):171–180
29.
Naylor KE, Iqbal P, Fledelius C, Fraser RB, Eastell R (2000) The effect of pregnancy on bone density and bone turnover. J Bone Miner Res 15(1):129–137PubMed
30.
Shaarawy M, El-Dawakhly AS, Mosaad M, El-Sadek MM (1999) Biomarkers of bone turnover and bone mineral density in hyperprolactinemic amenorrheic women. Clin Chem Lab Med 37(4):433–438PubMed
31.
Colao A, Di Somma C, Loche S, Di Sarno A, Klain M, Pivonello R, Pietrosante M, Salvatore M, Lombardi G (2000) Prolactinomas in adolescents: persistent bone loss after 2 years of prolactin normalization. Clin Endocrinol (Oxf) 52(3):319–327
32.
Di Somma C, Colao A, Di Sarno A, Klain M, Landi ML, Facciolli G, Pivonello R, Panza N, Salvatore M, Lombardi G (1998) Bone marker and bone density responses to dopamine agonist therapy in hyperprolactinemic males. J Clin Endocrinol Metab 83(3):807–813PubMed
33.
Mazziotti G, Biagioli E, Maffezzoni F, Spinello M, Serra V, Maroldi R, Floriani I, Giustina A (2015) Bone turnover, bone mineral density, and fracture risk in acromegaly: a meta-analysis. J Clin Endocrinol Metab 100(2):384–394PubMed
34.
Naliato EC, Farias ML, Braucks GR, Costa FS, Zylberberg D, Violante AH (2005) Prevalence of osteopenia in men with prolactinoma. J Endocrinol Invest 28(1):12–17PubMed
35.
Biller BM, Baum HB, Rosenthal DI, Saxe VC, Charpie PM, Klibanski A (1992) Progressive trabecular osteopenia in women with hyperprolactinemic amenorrhea. J Clin Endocrinol Metab 75(3):692–697PubMed
36.
Cann CE, Martin MC, Genant HK, Jaffe RB (1984) Decreased spinal mineral content in amenorrheic women. JAMA 251(5):626–629PubMed
37.
Naliato EC, Violante AH, Caldas D, Farias ML, Bussade I, Lamounier Filho A, Loureiro CR, Fontes R, Schrank Y, Loures T, Colao A (2008) Bone density in women with prolactinoma treated with dopamine agonists. Pituitary 11(1):21–28PubMed
38.
Klibanski A, Neer RM, Beitins IZ, Ridgway EC, Zervas NT, McArthur JW (1980) Decreased bone density in hyperprolactinemic women. N Engl J Med 303(26):1511–1514PubMed
39.
Klibanski A, Biller BM, Rosenthal DI, Schoenfeld DA, Saxe V (1988) Effects of prolactin and estrogen deficiency in amenorrheic bone loss. J Clin Endocrinol Metab 67(1):124–130PubMed
40.
Greenspan SL, Oppenheim DS, Klibanski A (1989) Importance of gonadal steroids to bone mass in men with hyperprolactinemic hypogonadism. Ann Intern Med 110(7):526–531PubMed
41.
Klibanski A, Greenspan SL (1986) Increase in bone mass after treatment of hyperprolactinemic amenorrhea. N Engl J Med 315:542–546PubMed
42.
Angeli A, Guglielmi G, Dovio A, Capelli G, de Feo D, Giannini S, Giorgino R, Moro L, Giustina A (2006) High prevalence of asymptomatic vertebral fractures in post-menopausal women receiving chronic glucocorticoid therapy: a cross-sectional outpatient study. Bone 39(2):253–259PubMed
43.
Lindsay R, Pack S, Li Z (2005) Longitudinal progression of fracture prevalence through a population of postmenopausal women with osteoporosis. Osteoporos Int 16(3):306–312PubMed
44.
Johansson H, Oden A, McCloskey EV, Kanis JA (2014) Mild morphometric vertebral fractures predict vertebral fractures but not non-vertebral fractures. Osteoporos Int 25(1):235–241PubMed
45.
Soto-Pedre E, Newey PJ, Bevan JS, Leese GP (2017) Morbidity and mortality in patients with hyperprolactinaemia: the PROLEARS study. Endocr Connect 6(8):580–588PubMedPubMedCentral
46.
Vestergaard P, Jørgensen JO, Hagen C, Hoeck HC, Laurberg P, Rejnmark L, Brixen K, Weeke J, Andersen M, Conceicao FL, Nielsen TL, Mosekilde L (2002) Fracture risk is increased in patients with GH deficiency or untreated prolactinomas—a case-control study. Clin Endocrinol (Oxf) 56(2):159–167
47.
Formenti AM, Tecilazich F, Giubbini R, Giustina A (2019) Risk of vertebral fractures in hypoparathyroidism. Rev Endocr Metab Disord 20(3):295–302PubMed
48.
Formenti AM, Doga M, Frara S, Ritelli M, Colombi M, Banfi G, Giustina A (2019) Skeletal fragility: an emerging complication of Ehlers-Danlos syndrome. Endocrine 63(2):225–230PubMed
49.
Genant HK, Delmas PD, Chen P, Jiang Y, Eriksen EF, Dalsky GP, Marcus R, Martin S (2007) J.: Severity of vertebral fracture reflects deterioration of bone microarchitecture. Osteoporos Int 18(1):69–76PubMed
50.
Mazziotti G, Doga M, Frara S, Maffezzoni F, Porcelli T, Cerri L, Maroldi R, Giustina A (2016) Incidence of morphometric vertebral fractures in adult patients with growth hormone deficiency. Endocrine 52(1):103–110PubMed
51.
Mazziotti G, Bianchi A, Porcelli T, Mormando M, Maffezzoni F, Cristiano A, Giampietro A, De Marinis L, Giustina A (2013) Vertebral fractures in patients with acromegaly: a 3-year prospective study. J Clin Endocrinol Metab 98(8):3402–3410PubMed
52.
Mazziotti G, Mancini T, Mormando M, De Menis E, Bianchi A, Doga M, Porcelli T, Vescovi PP, De Marinis L, Giustina A (2011) High prevalence of radiological vertebral fractures in women with prolactin-secreting pituitary adenomas. Pituitary 14(4):299–306PubMed
53.
Mazziotti G, Porcelli T, Mormando M, De Menis E, Bianchi A, Mejia C, Mancini T, De Marinis L, Giustina A (2011) Vertebral fractures in males with prolactinoma. Endocrine 39(3):288–293PubMed
54.
Mazziotti G, Frara S, Giustina A (2018) Pituitary diseases and bone. Endocr Rev 39(4):440–488PubMed
55.
Pedersini R, Amoroso V, Maffezzoni F, Gallo F, Turla A, Monteverdi S, Ardine M, Ravanelli M, Rodella F, Formenti AM, Dalla Volta A, Simoncini EL, Giustina A, Maroldi R, Berruti A (2019) Association of fat body mass with vertebral fractures in postmenopausal women with early breast cancer undergoing adjuvant aromatase inhibitor therapy. JAMA Netw Open 2(9):e1911080PubMedPubMedCentral
56.
Giustina A, Barkan A, Beckers A, Biermasz N, Biller BMK, Boguszewski C, Bolanowski M, Bonnert V, Bronstein MD, Casanueva FF, Clemmons D, Colao A, Ferone D, Fleseriu M, Frara S, Gadelha MR, Ghigo E, Gurnell M, Heaney AP, Ho K, Ioachimescu A, Katznelson L, Kelestimur F, Kopchick J, Krsek M, Lamberts S, Losa M, Luger A, Maffei P, Marazuela M, Mazziotti G, Mercado M, Mortini P, Neggers S, Pereira AM, Petersenn S, Puig-Domingo M, Salvatori R, Shimon I, Strasburger C, Tsagarakis S, van der Lely AJ, Wass J, Zatelli MC, Melmed S (2020) A consensus on the diagnosis and treatment of acromegaly comorbidities: an update. J Clin Endocrinol Metab. https://​doi.​org/​10.​1210/​clinem/​dgz096 CrossRefPubMedPubMedCentral
57.
Bonadonna S, Mazziotti G, Nuzzo M, Bianchi A, Fusco A, De Marinis L, Giustina A (2005) Increased prevalence of radiological spinal deformities in active acromegaly: a cross-sectional study in postmenopausal women. J Bone Miner Res 20(10):1837–1844PubMed
58.
Mazziotti G, Bianchi A, Bonadonna S, Cimino V, Patelli I, Fusco A, Pontecorvi A, De Marinis L, Giustina A (2008) Prevalence of vertebral fractures in men with acromegaly. J Clin Endocrinol Metab 93(12):4649–4655PubMed
59.
Schlechte JA, Sherman B, Martin R (1983) Bone density in amenorrheic women with and without hyperprolactinemia. J Clin Endocrinol Metab 56(6):1120–1123PubMed
60.
Pedersini R, Monteverdi S, Mazziotti G, Amoroso V, Roca E, Maffezzoni F, Vassalli L, Rodella F, Formenti AM, Frara S, Maroldi R, Berruti A, Simoncini E, Giustina A (2017) Morphometric vertebral fractures in breast cancer patients treated with adjuvant aromatase inhibitor therapy: A cross-sectional study. Bone 97:147–152PubMed
61.
62.
Petersenn S, Giustina A (2020) Diagnosis and management of prolactinomas: current challenges. Pituitary 23:1PubMed
63.
64.
Huhn H, Nikolakopoulou A, Schneider-Thoma J, Krause M, Samara M, Peter N, Arndt T, Bäckers L, Rothe P, Cipriani A, Davis J, Salanti G, Leucht S (2019) Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis. Lancet 394(10202):939–951PubMedPubMedCentral
65.
Mancini T, Casanueva FF, Giustina A (2008) Hyperprolactinemia and prolactinomas. Endocrinol Metab Clin North Am 37(1):67–99PubMed
66.
Smith S, Wheeler M, Murray R, O’Keane V (2002) The effects of anti-psychotic induced hyperprolactinaemia on the hypothalamic-pituitary-gonadal axis. J Clin Psychopharmacol 22:109–114PubMed
67.
Howes OD, Wheeler MJ, Pilowsky LS, Landau S, Murray RM, Smith S (2007) Sexual function and gonadal hormones in patients taking antipsychotic treatment for schizophrenia or schizoaffective disorder. J Clin Psychiatry 68(3):361–367PubMedPubMedCentral
68.
Pacchiarotti I, Murru A, Kotzalidis GD, Bonnin CM, Mazzarini L, Colom F, Vieta E (2015) Hyperprolactinemia and medications for bipolar disorder: systematic review of a neglected issue in clinical practice. Eur Neuropsychopharmacol 25(8):1045–1059PubMed
69.
Crews MP, Howes OD (2012) Is antipsychotic treatment linked to low bone mineral density and osteoporosis? A review of the evidence and the clinical implications. Hum Psychopharmacol 27(1):15–23PubMedPubMedCentral
70.
Lally J, Sahl AB, Murphy KC, Gaughran F, Stubbs B (2019) Serum Prolactin and Bone Mineral Density in Schizophrenia: A Systematic Review. Clin Psychopharmacol Neurosci 17(3):333–342PubMedPubMedCentral
71.
Wang M, Hou R, Jian J, Mi G, Qiu H, Cao B, Tang M (2014) Effects of antipsychotics on bone mineral density and prolactin levels in patients with schizophrenia: a 12-month prospective study. Hum Psychopharmacol 29:183–189PubMed
72.
Pouwels S, van Staa TP, Egberts AC, Leufkens HG, Cooper C, de Vries F (2009) Antipsychotic use and the risk of hip/femur fracture: a population-based case-control study. Osteoporos Int 20:1499–1506PubMedPubMedCentral
73.
Bolton JM, Targownik LE, Leung S, Sareen J, Leslie WD (2011) Risk of low bone mineral density associated with psychotropic medications and mental disorders in postmenopausal women. J Clin Psychopharmacol 31:56–60PubMed
74.
Bakken MS, Schjøtt J, Engeland A, Engesaeter LB, Ruths S (2016) Antipsychotic drugs and risk of hip fracture in people aged 60 and older in Norway. J Am Geriatr Soc 64:1203–1209PubMed
75.
Lee SH, Hsu WT, Lai CC, Esmaily-Fard A, Tsai YW, Chiu CC, Wang J, Chang SS, Lee CC (2017) Use of antipsychotics increases the risk of fracture: a systematic review and meta-analysis. Osteoporos Int 28(4):1167–1178PubMed
76.
Mazziotti G, Canalis E, Giustina A (2010) Drug-induced osteoporosis: mechanisms and clinical implications. Am J Med 123(10):877–884PubMed
77.
Bouillon R, Marcocci C, Carmeliet G, Bikle D, White JH, Dawson-Hughes B, Lips P, Munns CR, Lazaretti-Castro M, Giustina A, Bilezikian J (2019) Skeletal and extraskeletal actions of vitamin D: current evidence and outstanding questions. Endocr Rev 40(4):1109–1151PubMed
78.
Giustina A, Adler RA, Binkley N, Bollerslev J, Bouillon R, Dawson-Hughes B, Ebeling PR, Feldman D, Formenti AM, Lazaretti-Castro M, Marcocci C, Rizzoli R, Sempos CT, Bilezikian JP (2020) Consensus statement from 2nd International Conference on Controversies in Vitamin D. Rev Endocrinol Metab Disord. https://​doi.​org/​10.​1007/​s11154-019-09532-w CrossRef
79.
Muench J, Hamer AM (2010) Adverse effects of antipsychotic medications. Am Fam Physician 81(5):617–622PubMed
80.
Chisholm D, Gureje O, Saldivia S (2008) Schizophrenia treatment in the developing world: an interregional and multinational cost-effectiveness analysis. Bull World Health Organ 86:542–551PubMedPubMedCentral
81.
Coronas R, Cobo J, Giménez-Palop O, Ortega E, Márquez M (2012) Safety of cabergoline in the management of pituitary prolactin-induced symptoms with patients treated with atypical neuroleptics. Curr Drug Saf 7(2):92–98PubMed
82.
Kalkavoura CS, Michopoulos I, Arvanitakis P, Theodoropoulou P, Dimopoulou K, Tzebelikos E, Lykouras L (2013) Effects of cabergoline on hyperprolactinemia, psychopathology, and sexual functioning in schizophrenic patients. Exp Clin Psychopharmacol 21(4):332–341PubMed
83.
Jano E, Johnson M, Chen H, Aparasu RR (2008) Determinants of atypical antipsychotic use among antipsychotic users in community-dwelling elderly, 1996–2004. Curr Med Res Opin 24(3):709–716PubMed
84.
Mazziotti G, Formenti AM, Frara S, Olivetti R, Banfi G, Memo M, Maroldi R, Giubbini R, Giustina A (2018) High prevalence of radiological vertebral fractures in women on thyroid-stimulating hormone-suppressive therapy for thyroid carcinoma. J Clin Endocrinol Metab 103(3):956–964PubMed
85.
Mazziotti G, Formenti AM, Adler RA, Bilezikian JP, Grossman A, Sbardella E, Minisola S, Giustina A (2016) Glucocorticoid-induced osteoporosis: pathophysiological role of GH/IGF-I and PTH/VITAMIN D axes, treatment options and guidelines. Endocrine 54(3):603–611PubMed
86.
Gomez L, Stubbs B, Shirazi A, Vancampfort D, Gaughran F, Lally J (2016) Lower bone mineral density at the hip and lumbar spine in people with psychosis versus controls: a comprehensive review and skeletal site-specific meta-analysis. Curr Osteoporos Rep 14(6):249–259PubMedPubMedCentral
87.
Weaver J, Kawsky J, Corboy A (2019) Antipsychotic use and fracture risk: an evaluation of incidence at a veterans affairs medical center. Ment Health Clin 9(1):6–11PubMedPubMedCentral
88.
Giustina A, Adler RA, Binkley N, Bouillon R, Ebeling PR, Lazaretti-Castro M, Marcocci C, Rizzoli R, Sempos CT, Bilezikian JP (2019) Controversies in vitamin D: summary statement from an international conference. J Clin Endocrinol Metab 104(2):234–240PubMed
89.
Sempos CT, Heijboer AC, Bikle DD, Bollerslev J, Bouillon R, Brannon PM, DeLuca HF, Jones G, Munns CF, Bilezikian JP, Giustina A, Binkley N (2018) Vitamin D assays and the definition of hypovitaminosis D: results from the first international conference on controversies in vitamin D. Br J Clin Pharmacol 84(10):2194–2207PubMedPubMedCentral
90.
Mazziotti G, Bilezikian J, Canalis E, Cocchi D, Giustina A (2012) New understanding and treatments for osteoporosis. Endocrine 41(1):58–69PubMed
91.
Canalis E, Giustina A, Bilezikian JP (2007) Mechanisms of anabolic therapies for osteoporosis. N Engl J Med 30(9):905–916 357)
Metadaten
Titel
Hyperprolactinemia and bone
verfasst von
Luigi di Filippo
Mauro Doga
Eugenia Resmini
Andrea Giustina
Publikationsdatum
26.03.2020
Verlag
Springer US
Erschienen in
Pituitary / Ausgabe 3/2020
Print ISSN: 1386-341X
Elektronische ISSN: 1573-7403
DOI
https://doi.org/10.1007/s11102-020-01041-3

Weitere Artikel der Ausgabe 3/2020

Growth hormone therapy in adults with growth hormone deficiency: a critical assessment of the literature

Pituitary metastases: presentation and outcomes from a pituitary center over the last decade

  • Open Access

MRI texture analysis in acromegaly and its role in predicting response to somatostatin receptor ligands

Pituitary neuroendocrine tumors (PitNETs): nomenclature evolution, not clinical revolution

Multi-syphilitic gummas in pituitary and cerebellopontine angle in a patient

Do nothing but observe microprolactinomas: when and how to replace sex hormones?

Kompaktes Leitlinien-Wissen Innere Medizin (Link öffnet in neuem Fenster)

Mit medbee Pocketcards schnell und sicher entscheiden.
Leitlinien-Wissen kostenlos und immer griffbereit auf ihrem Desktop, Handy oder Tablet.

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Verbände und Cremes gegen Dekubitus: „Wir wissen nicht, was sie bringen!“

Die Datenlage zur Wirksamkeit von Verbänden oder topischen Mitteln zur Prävention von Druckgeschwüren sei schlecht, so die Verfasser einer aktuellen Cochrane-Studie. Letztlich bleibe es unsicher, ob solche Maßnahmen den Betroffenen nutzen oder schaden.

Schützt das tägliche Glas Milch vor Darmkrebs?

Die Milch machts – sie bietet Frauen nach Daten einer großen Ernährungsanalyse den besten Darmkrebsschutz aller Lebensmittel, was am hohen Kalziumgehalt liegen dürfte. Am anderen Ende des Spektrums steht der Alkoholkonsum: Das Glas Wein am Abend ist eher ungünstig.

Vorsicht mit Glukokortikoiden bei Glomerulopathie

Auch niedrig dosierte Glukokortikoide zur Behandlung einer primären Glomerulopathie lassen offenbar die Infektionsgefahr steigen. In einer US-Studie hing das Risiko vor allem mit der kombinierten Anwendung von Immunsuppressiva zusammen.

KI-gestütztes Mammografiescreening überzeugt im Praxistest

Mit dem Einsatz künstlicher Intelligenz lässt sich die Detektionsrate im Mammografiescreening offenbar deutlich steigern. Mehr unnötige Zusatzuntersuchungen sind laut der Studie aus Deutschland nicht zu befürchten.

EKG Essentials: EKG befunden mit System (Link öffnet in neuem Fenster)

In diesem CME-Kurs können Sie Ihr Wissen zur EKG-Befundung anhand von zwölf Video-Tutorials auffrischen und 10 CME-Punkte sammeln.
Praxisnah, relevant und mit vielen Tipps & Tricks vom Profi.

Jetzt 10 CME-Punkte sammeln

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise